Biogen Inc.
Market Data Current As Of: September 12, 2026
Related Competitor Intelligence
Compare market positioning with top industry peers
Explore Biogen
Core profile pages, annual revenue records, and related research hubs for this company.
Biogen Inc.
Compare market positioning with top industry peers
Explore Biogen
Core profile pages, annual revenue records, and related research hubs for this company.
Financial Performance
Revenue
$9.9B
Market Cap
$32.4B
Net Income
$1.3B
Employees
8,725
Biogen's financial narrative in 2026 is defined by an aggressive corporate reboot following the catastrophic commercial failure and reputational damage of its controversial Alzheimer's drug, Aduhelm. Under CEO Christopher A. Viehbacher, the biotechnology firm generated exactly $9.8 billion in revenue and maintains a $32.4 billion market cap with a workforce of exactly 8725 employees. To offset declining revenues from its legacy multiple sclerosis franchise (which is facing severe generic competition), Biogen has slashed its headcount and R&D footprint. The company's future now rests entirely on the commercial launch of Leqembi, a newer, clinically validated Alzheimer's treatment partnered with Eisai, though it faces logistical hurdles regarding Medicare reimbursement and competition from Eli Lilly.
Revenue Trend Analysis
YoY Change
+2.9%
2-Year CAGR
+0.3%
Peak Year
2025
Trend
Mostly Growing
Biogen Inc. has reported revenue across 3 fiscal years, compounding at +0.3% annually over 2 years. The most recent year saw a 2.9% increase versus the prior year. Revenue peaked in 2025 at $9.9B. Out of 2 reported periods, 1 showed growth and 1 showed a decline.
| Fiscal Year | Revenue | Net Income | YoY Change |
|---|---|---|---|
| FY2025 | $9.9B | $1.3B | +2.9% |
| FY2024 | $9.6B | — | -2.3% |
| FY2023 | $9.8B | — | — |
Source: SEC EDGAR filings, annual earnings releases, and verified financial disclosures.
Click any row to see year details.
Biogen Inc. reported approximately $9.8B in fiscal year 2025 with a team of 8,725 employees worldwide.
Biogen Inc. strategically balances reinvestment into core R&D with operational cost discipline, focusing on workflow automation to expand operating margins in 2026.
Financial performance in Biotechnology and Pharmaceuticals is driven by steady cash generation and pricing power, enabling Biogen Inc. to reinvest in high-return strategic initiatives.
Using these figures? Please credit CorpDigest with a link.
CorpDigest. "Biogen Inc. Revenue & Financials." CorpDigest, https://corpdigest.com/company/biogen/financials.<div style="font-family:system-ui,sans-serif;font-size:14px;line-height:1.5;border:1px solid #e2e8f0;border-radius:8px;padding:12px 16px;max-width:520px"><strong>Biogen Inc. reported $10B in revenue (FY2025).</strong><br>Source: <a href="https://corpdigest.com/company/biogen/financials" target="_blank" rel="noopener">CorpDigest — Biogen Inc. financials</a></div>